GoBear is now part of Finder
Picture not described

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cynata Therapeutics (CYP) shares

Learn how to easily invest in Cynata Therapeutics shares.

Cynata Therapeutics Limited is a biotechnology business based in Australia. Cynata Therapeutics shares (CYP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars.

How to buy shares in Cynata Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Compare online brokers

Name Product Number of Stocks Shares Available Markets
Interactive Brokers
Access to global markets
Yes
Global markets
Your capital is at risk.
Saxo Markets
19,000+
Yes
Global markets
Your capital is at risk.
Plus500
2,000+
No
US, UK, AU, DE, FR, IT, PT, GR, JP, SG, ZA, NL, FI, BE, DK, SE, CH, ES, AT, NO, HU, CZ, IE, PL, HK
CFD Service. Your capital is at risk.
BlackBull Markets
N/A
No
UK, HK, JP, MY, NZ, US
CFD Service. Your capital is at risk.
Libertex
50+
No
Worldwide with exception.
Except for: US/Australia/New Zealand/Belgium/British Virgin Islands/Guam/Lebanon/United States Minor/Outlying Islands/Northern Mariana Islands/Uganda/Philippines/Sri Lanka/Kuwait/South Africa/Azerbaijan/Canada/Armenia/Russia/Japan/Brasil.
CFD Service. Your capital is at risk.
Exness
N/A
No
CH, VN, TH, PH, SG, ID, IN, UAE, ZA, SA, EG, BR, CR, MX
CFD Service. Your capital is at risk.
IG
17,000+
No
DK, IE, NO, RU, DE, IT, AT, CH, ES, LU, PT, SE, FR, NL, RO, UK, US, AU, JP, SG, ZA, AE
CFD Service. Your capital is at risk.
loading

Compare up to 4 providers

How has Coronavirus impacted Cynata Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Cynata Therapeutics's stock price has had significant negative movement.

Its last market close was A$0.615, which is 43.06% down on its pre-crash value of A$1.08 and 6.03% up on the lowest point reached during the March crash when the stocks fell as low as A$0.58.

If you had bought A$1,000 worth of Cynata Therapeutics stocks at the start of February 2020, those stocks would have been worth A$581.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth A$572.09.

Is it a good time to buy Cynata Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cynata Therapeutics shares at a glance

Information last updated 2021-10-15.
Latest market closeA$0.62
52-week rangeA$0.47 - A$0.93
50-day moving average A$0.57
200-day moving average A$0.56
Wall St. target priceA$2.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) A$-0.06

Cynata Therapeutics stock price (Australian Securities Exchange (ASX): CYP)

Use our graph to track the performance of CYP stocks over time.

Cynata Therapeutics price performance over time

Historical closes compared with the close of A$0.615 from 2021-10-18

1 week (2021-10-11) 0.82%
1 month (2021-09-17) 8.85%
3 months (2021-07-16) 20.59%
6 months (2021-04-16) 2.50%
1 year (2020-10-16) -26.35%
2 years (2019-10-18) -54.10%
3 years (2018-10-18) 1.25
5 years (2016-10-18) 8.85%

Cynata Therapeutics financials

Revenue TTM A$1.5 million
Gross profit TTM A$1.5 million
Return on assets TTM -19.85%
Return on equity TTM -34.05%
Profit margin 0%
Book value A$0.20
Market capitalisation A$90.3 million

TTM: trailing 12 months

Cynata Therapeutics share dividends

We're not expecting Cynata Therapeutics to pay a dividend over the next 12 months.

Have Cynata Therapeutics's shares ever split?

Cynata Therapeutics's shares were split on a 1:20 basis on 30 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cynata Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cynata Therapeutics shares which in turn could have impacted Cynata Therapeutics's share price.

Cynata Therapeutics share price volatility

Over the last 12 months, Cynata Therapeutics's shares have ranged in value from as little as A$0.47 up to A$0.93. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cynata Therapeutics's is 0.3281. This would suggest that Cynata Therapeutics's shares are less volatile than average (for this exchange).

Cynata Therapeutics overview

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. .

Stocks similar to Cynata Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask Finder

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked
Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy Policy and Terms.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site